INDP · Insider Trading
Indaptus Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by INDP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-24 | David E. Lazar | Director | Sell | −896,800 deriv. | — |
| 2026-02-27 | Jerome D Jabbour | Director | A | +25,000 deriv. | — |
| 2026-02-13 | Jeffrey A Meckler | Co-Chief Executive Officer | MIXED | — | — |
| 2026-01-22 | Avraham Ben-Tzvi | Director | A | +25,000 | — |
| 2026-01-22 | David Natan | Director | A | +25,000 deriv. | — |
| 2025-12-29 | Nir Sassi | Chief Financial Officer | A | +26,758 | +$54.32K |
| 2025-12-29 | Walt Addison Linscott | Chief Operating Officer | A | +54,421 | +$110.47K |
| 2025-12-29 | Michael James Newman | CSO and Director | A | +52,204 | +$105.97K |
| 2025-12-29 | Jeffrey A Meckler | Co-Chief Executive Officer | A | +216,617 | +$439.73K |
| 2025-07-29 | Jeffrey A Meckler | Chief Executive Officer | A | +6,068 | +$50.38K |
| 2025-06-11 | William B Hayes | Director | A | +12,500 deriv. | — |
| 2025-06-11 | Hila Karah | Director | A | +12,500 deriv. | — |
| 2025-06-11 | Anthony J Maddaluna | Director | A | +12,500 deriv. | — |
| 2025-06-11 | Robert Martell | Director | A | +12,500 deriv. | — |
| 2025-06-11 | Roger Pomerantz | Director | A | +30,000 deriv. | — |
| 2025-06-11 | Mark John Gilbert | Director | A | +12,500 deriv. | — |
| 2025-04-11 | Anthony J Maddaluna | Director | D | −1,000 deriv. | — |
| 2025-04-11 | Nir Sassi | Chief Financial Officer | D | −6,541 deriv. | — |
| 2025-04-11 | Roger Pomerantz | Director | D | −1,000 deriv. | — |
| 2025-04-11 | Hila Karah | Director | D | −1,281 deriv. | — |
| 2025-04-11 | Jeffrey A Meckler | Chief Executive Officer | D | −13,626 deriv. | — |
| 2025-04-11 | Walt Addison Linscott | Chief Operating Officer | D | −8,500 deriv. | — |
| 2025-04-11 | William B Hayes | Director | D | −1,000 deriv. | — |
| 2024-11-26 | Jeffrey A Meckler | CEO and Director | A | +42,553 | +$50.00K |
| 2024-10-10 | Michael James Newman | CSO and Director | A | +75,000 deriv. | — |
| 2024-10-10 | Roger J. Waltzman | Chief Medical Officer | A | +75,000 deriv. | — |
| 2024-10-10 | Nir Sassi | Chief Financial Officer | A | +75,000 deriv. | — |
| 2024-10-10 | Walt Addison Linscott | Chief Operating Officer | A | +75,000 deriv. | — |
| 2024-10-10 | Jeffrey A Meckler | CEO and Director | A | +75,000 deriv. | — |
| 2024-08-08 | Jeffrey A Meckler | CEO and Director | A | +84,932 | +$155.00K |
| 2024-06-07 | Hila Karah | Director | A | +12,500 deriv. | — |
| 2024-06-07 | Mark John Gilbert | Director | A | +12,500 deriv. | — |
| 2024-06-07 | Roger Pomerantz | Director | A | +30,000 deriv. | — |
| 2024-06-07 | Robert Martell | Director | A | +12,500 deriv. | — |
| 2024-06-07 | Anthony J Maddaluna | Director | A | +12,500 deriv. | — |
| 2024-06-07 | William B Hayes | Director | A | +12,500 deriv. | — |
| 2024-01-23 | Jeffrey A Meckler | CEO and Director | A | +100,000 deriv. | — |
| 2024-01-23 | Nir Sassi | Chief Financial Officer | A | +40,000 deriv. | — |
| 2024-01-23 | Roger J. Waltzman | Chief Medical Officer | A | +75,000 deriv. | — |
| 2024-01-23 | Walt Addison Linscott | Chief Operating Officer | A | +75,000 deriv. | — |
| 2024-01-23 | Michael James Newman | CSO and Director | A | +43,250 deriv. | — |
| 2023-08-16 | Glen R. Anderson | 10%+ Owner | Buy | +103,352 | +$216.39K |
| 2023-08-07 | Roger J. Waltzman | Chief Medical Officer | A | +90,000 deriv. | — |
| 2023-05-30 | William B Hayes | Director | A | +12,500 deriv. | — |
| 2023-05-30 | Mark John Gilbert | Director | A | +12,500 deriv. | — |
| 2023-05-30 | Anthony J Maddaluna | Director | A | +12,500 deriv. | — |
| 2023-05-30 | Roger Pomerantz | Director | A | +30,000 deriv. | — |
| 2023-05-30 | Hila Karah | Director | A | +12,500 deriv. | — |
| 2023-02-14 | Robert Martell | Director | A | +20,000 deriv. | — |
| 2023-01-20 | Walt Addison Linscott | Chief Business Officer | A | +40,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jeffrey A Meckler | Co-Chief Executive Officer | 229,929 | $508.14K |
| Michael James Newman | CSO and Director | 149,944 | $331.38K |
| Walt Addison Linscott | Chief Operating Officer | 54,426 | $120.28K |
| Nir Sassi | Chief Financial Officer | 26,758 | $59.14K |
| Avraham Ben-Tzvi | Director | 25,100 | $55.47K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INDP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.